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roid hormone receptors (VDR and ER
) together with analysis
of NOD2/CARD15 mutations previously shown to be associ-
ated with GvHD and survival; clinical factors such as recipient
age, gender mismatch (female donor/male recipient), CMV sta-
tus, disease stage and stem cell source were included in the
analysis. Statistical modelling was carried out using binary lo-
gistic regression (for GvHD) and Cox regression (for survival).
Step-wise variable selection was used to identify a good set of
predictors of response. The prognostic index was a weighted
linear combination of these predictors and predictive accuracy
assessed for GvHD models. For the total cohort a good predic-
tive model for GvHD II-IV included absence of patient/donor
VDR and presence of patient IFN3/3 genotype; female to male
transplants; PBSC transplant and absence of T-cell depletion
(sensitivity 62%). GvHD associated with reduced intensity con-
ditioning occurred with the presence of patient/donor IL-1R

genotype, absence of VDR-1 donor genotype and absence of T
cell depletion (sensitivity 60%; overall correct prediction 77%).
In the acute leukaemia sub-group presence of patient IL-6 and
IFN genotype and absence of donor VDR-1 genotype inﬂu-
enced GvHD II-IV (64% sensitivity; overall correct prediction
68%). In the sub-group 	16 years the MDR-1 (12 allele A)
together with NOD2/CARD15 mutations inﬂuenced GvHD
outcome (speciﬁcity 58% sensitivity 80% overall correct pre-
diction 71%—Hosmer-Lemeshow test P  .896). Survival mod-
elling (162 of 244), using Cox regression for all data showed that
female to male transplants, donor age 	40 and CMV positivity
together with absence of IFN3/3 donor genotype and presence
of any NOD2 variable in the patient were the most signiﬁcant
variables and the best predictors of decreased survival.
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CHARACTERIZATION OF T CELL SPECIFICITIES RESPONSIBLE FOR DIF-
FERENTIAL GVHD AND ANTI-TUMOR-REACTIVITY INDUCED BY DONOR
LYMPHOCYTE INFUSION
Falkenburg, J.H.F.1, Slager, I.1, van Bergen, K.1, van Kester, M.1,
Jedema, I.1, van Luxemburg-Heijs, S.1, Heemskerk, M.1, Willemze, R.1
1Leiden University Medical Center, Leiden, The Netherlands.
Direct cloning using cell sorting of tumor-reactive T cells
from patients successfully responding to donor lymphocyte in-
fusion (DLI) as a treatment of relapsed leukemia or multiple
myeloma after allogeneic stem cell transplantation (SCT) re-
vealed the simultaneous presence of multiple clonal T cell
responses capable of killing the malignant cells during the clin-
ical response. In addition to the presence of known minor
histocompatibility antigen (mHag) speciﬁc T cell responses
against HA-1, HA-2, BCL2-A1 and HY, two new mHag were
identiﬁed. One of the speciﬁcities was characterized to be de-
rived from the endothelial cell growth factor-1 (ECGF-1) gene.
In addition, a new HLA-A2 restricted mHag derived from an
alternative reading frame from a broadly expressed protein was
found to be a target for one of the dominant T cell responses in
a patient with multiple myeloma responding to DLI. Some of
these mHags were exclusively expressed in hematopoietic cells,
whereas others were broadly expressed in both hematopoietic
and non-hematopoietic cells. Despite the broad tissue distribu-
tion of some mHag we found high frequencies of these mHag
speciﬁc T cells up to 3% of circulating T cells also in patients
suffering from only limited GVHD. These results illustrated
that not only the tissue distribution of the proteins indicated the
balance between GVHD and graft versus tumor (GVT) reac-
tivity. Using a panel of primary target cells we demonstrated
differential recognition of non-activated versus activated cells
from patients and donors by T cells speciﬁc for broadly ex-
pressed antigen. The activation state of the target cells corre-
sponded with the recognition by certain T cells against broadly
expressed antigens, whereas T cells recognizing hematopoiesis
speciﬁc mHag like HA-1 were capable of killing both activated
and non-activated hematopoietic cells. Our results illustrate that
T cell responses against broadly expressed antigens can mediate
a GVT reactivity with no or limited GVHD in patients not
suffering from concurrent diseases. These results also explain an
increased susceptibility of target organs for recognition by
mHag speciﬁc T cells during infectious diseases resulting in
increased GVHD.
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DIFFERENTIAL EFFECTS OF ORGAN-DERIVED HOST-TYPE DENDRITIC
CELLS ON ALLOREACTIVE DONOR T CELLS IN A MURINE BONE MAR-
ROW TRANSPLANTATION MODEL
Kim, T.D.1, Zakrzewski, J.L.1, Kochman, A.1, Suh, D.1,
Terwey, T.H.1, Borsotti, C.1, van den Brink, M.R.1 1Department of
Medicine and Immunology, Memorial Sloan-Kettering Cancer Center,
New York, NY.
Host dendritic cells are considered critical for the induction of
graft-versus-host disease. In addition to their priming function,
dendritic cells were recently shown to induce organ-tropism de-
pending on their tissue of origin. Here, we sought to examine the
effect of different organ-derived dendritic cells on allogeneic T
cells and their capacity to induce GvHD. FLT3L-expanded host-
type dendritic cells from GvHD target organs (liver, spleen) or
their draining secondary lymphoid tissues (peripheral lymph nodes
for skin, mesenteric lymph nodes for gut) effectively primed naı¨ve
splenic donor-type T cells after short-term coculture in vitro.
Overall levels of alloreactivity as analysed by expression of activa-
tion markers, detection of cytokine secretion and in vitro prolifer-
ation in an MLR were comparable. However, there were signiﬁ-
cantly divergent expression patterns of homing molecules between
gut-derived and all other dendritic cell types. Whereas the expres-
sion of the intestinal homing molecule LPAM-1 (alpha-4, beta-7
integrin) was signiﬁcantly higher on T cells stimulated with gut-
derived dendritic cells, the expression of E- and P-selectin ligands
was signiﬁcantly lower. Interestingly, the expression of E-selectin
ligands was preferentially induced on CD8 T cells, whereas the
upregulation of P-selectin ligands was comparable on CD4 and
CD8 T cells. Both LPAM-1 subunits were upregulated with
alpha-4 integrin being the highest and being associated with up-
regulation of VLA-4 (alpha-4, beta-1 integrin) which has previ-
ously been implicated in liver homing. However, the latter was not
induced by liver-derived dendritic cells. In a murine bone marrow
transplantation model (B10.BR into B6, 1  106 T cells) these
cultured T cells expectedly induced less aggressive GvHD as com-
pared to naive control T cells with the exception of T cells stim-
ulated with dendritic cells from mesenteric lymph nodes. Survival
in this group was signiﬁcantly shorter than in the spleen, liver and
peripheral lymph node groups and not different from the control T
cell group. In conclusion, we have shown for the ﬁrst time that
dendritic cells can efﬁciently induce speciﬁc homing molecules on
alloreactive T cells and that an induced ‘gut-homing phenotype’
correlates with increased GvHD mortality after murine bone mar-
row transplantation.
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THE DETECTION OF ACTIVATED CIRCULATING CMRF-44 POSITIVE
CD11c DENDRITIC CELLS IS CLOSELY ASSOCIATED WITH THE SE-
VERITY OF ACUTE GVHD AFTER ALLOGENEIC HEMOPOIETIC STEM
CELL TRANSPLANT
Lau, J.1, Sartor, M.1, Vuckovic, S.2, Munster, D.2, Bradstock, K.3,
Hart, D.2 1Westmead Millenium Institute, Sydney, New South Wales,
Australia; 2Mater Medical Research Institute, Brisbane, Queensland,
Australia; 3BMT Service, Westmead Hospital, Sydney, New South
Wales, Australia.
Dendritic cells (DC) are considered central to the development
of graft versus host disease (GVHD) following allogeneic hemo-
poietic stem cell transplantation (alloHSCT). Both donor and host
DC are thought to initiate allogeneic immune responses by pre-
senting host antigens to donor T lymphocytes. We prospectively
studied the potential of the monoclonal antibody CMRF-44 to
identify activated circulating blood DC, as a predictive marker of
acute GVHD. Peripheral blood was taken from 40 patients, twice
Oral Presentations
12
weekly up to 100 days post-alloHSCT. Circulating myeloid
(CD11chi) and plasmacytoid (CD123hi) DCs were enumerated and
the expression of CMRF-44 was assessed on CD11chi DC by four
colour ﬂow cytometry. Multivariate analyses were performed using
a non-parametric Mann-Whitney U-test and receiver operating
characteristic (ROC) curves. Following alloHSCT, the severity of
acute GVHD correlated with the number of total DC in the blood
(P  .035). Furthermore, low myeloid and plasmacytoid DC num-
bers were signiﬁcantly associated with grade 2-4 acute GVHD
(P  .046 and .017 respectively). In 40 alloHSCT patients, 27
developed acute GVHD. CMRF-44 was expressed on CD11c
DC in all cases prior to the onset of acute GVHD. Of the 13
patients without GVHD, 8 had no circulating CMRF-44
CD11cDC. CMRF-44 expression was independent of the recon-
stitution of myeloid DC (P  .73). Patients who had CMRF-44
CD11c DC in more than 20% of their post-transplant monitor-
ing samples were more likely to develop acute GVHD (P  .001,
OR  37.1). In addition, patients with more severe grade 2-4
GVHD had signiﬁcantly higher percentages of CMRF-44
CD11c DCs (P  .001). CMRF-44 expression at greater than or
equal to 12% of CD11chi DCs had a sensitivity of 87.5 for predic-
tion of grade 2-4 acute GVHD and a speciﬁcity of 91.7. We
conclude that CMRF-44 expression on blood CD11c DC is
highly associated with the onset of acute GVHD. The detection of
circulating activated DCs may be used as a predictive tool to
identify patients at risk of severe GVHD and potentially to direct
therapy. Our data also reinforces the potential for suitably engi-
neered CMRF-44 or other antibodies directed at DC activation
antigens to prevent or treat GVHD.
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DETERMINING PROGNOSIS FOR PATIENTS WITH ACUTE GVHD IN REAL
TIME: DEVELOPMENT AND TESTING OF AN ACUTE GVHD ACTIVITY
INDEX
McDonald, G.B.1, Leisenring, W.M.1, Martin, P.J.1 1Fred Hutchinson
Cancer Research Center, Seattle, WA.
The current scoring systems for acute GVHD are problematic
due to the retrospective assignment of scores, lack of consideration
for the efﬁcacy of treatment, and inter-observer error. An evi-
dence-based, real-time system for scoring GVHD would be useful
for determining prognosis in individual patients and for quantify-
ing the burden of GVHD across time.Methods:We examined the
severity of signs and symptoms of GVHD from its onset to day 100
in 386 patients with CML who underwent allogeneic transplant
after a myeloablative regimen. During each 10 day period to day
100, a unique letter designation was assigned for each degree of
abnormality in skin, liver, upper gastrointestinal tract, lower gas-
trointestinal tract, immunosuppressive drugs, fever, and perfor-
mance status, respectively. We used a training data set of 193
randomly selected patients, logistic regression methods, and re-
ceiver-operator curves for optimizing the model, to create an
activity index (aGVHDAI) that predicts non-relapse mortality at
day 200. Scaling was carried out by dividing the coefﬁcients in the
logistic regression model by the sum of the coefﬁcients and mul-
tiplying this proportion by 100. The ﬁnal aGVHDAI was then
applied to an independent, 193-patient data set, testing the accu-
racy of the index to predict day 200 non-relapse mortality. Results:
Parameters entering the optimal aGVHDAI model included the
level of jaundice, caloric intake, need for prednisone therapy, and
performance score. Skin GVHD, volume of diarrhea, and presence
of fever did not improve the model’s predictive ability (Table 1).
The area under a receiver-operator curve for the ﬁnal average
aGVHDAI model in the training data set, using non-relapse mor-
tality at day 200 as the end point, was 0.87. When the model was
then applied to an independent data set of 193 patients, the area
under an ROC curve was 0.85. Using the same aGVHD activity
index parameters, a graphic was developed that allows prediction of
non-relapse mortality at day 200 (on the vertical axis) for individual
patients, based on the aGVHDAI at any point in time after trans-
plant (on the horizontal axis). Conclusions: An acute GVHD
activity index has been tested that allows prediction of non-relapse mor-
tality in real-time and provides investigators with a research tool for
assessing the burden of acute GVHDover time. This aGVHDAI, scaled
from 0-100, is based on serum bilirubin levels, caloric intake, need for
prednisone therapy, and performance status.
Table 1. Components of the Acute GVHD Activity Index with
Weighting Factors for Each component
Factor Scoring Level
Scaled Weight-
ing Factor
Liver dys-
function
Total serum bilirubin 2–4 mg/
dL
16
Total serum bilirubin >5 mg/
dL
26
Upper GI
tract
Oral caloric intake <40%, with
poorly controlled anorexia,
nausea, or vomiting
20
Immuno-
suppressive
therapy
Any prednisone dose or
secondary therapy for
GVHD
17
Performance
status
Ambulatory but restricted in
strenuous activity
20
Limited self-care, more than
50% of time in bed, or worse
37
The scale is from 0 to 100, with the end point of day 200 non-
relapse mortality.
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THE CYTOKINE STORM AND ACUTE GRAFT-VERSUS-HOST DISEASE
(aGVHD) AFTER REDUCED INTENSITY CONDITIONING (RIC) ALLOGE-
NEIC STEM CELL TRANSPLANTATION (allo-SCT)
Mohty, M.1, Gaugler, B.2, Faucher, C.1, Furst, S.1, Olive, D.2,
Blaise, D.1 1Institut Paoli-Calmettes, Marseille, France; 2INSERM
UMR 599, Marseille, France.
The use of RIC regimens has modiﬁed the natural history of
transplant-related complications, especially aGVHD. The aim of
this study was to investigate the role of inﬂammatory cytokines on
aGVHD incidence and severity in 113 patients who received a RIC
allo-SCT from an HLA-identical sibling. Plasma levels of 10 dif-
ferent cytokines (IL-1beta, IL-6, IL-8, IL-10, IL-12p70, IL-18,
TNF-
, IFN-
, IFN-, and Fas-L) were measured by ELISA
prior to allo-SCT, at day 0 prior to graft infusion, and at regular
times within the ﬁrst 3 months after allo-SCT. Except for IL-
12p70, all measured cytokines showed little variations in the blood
in the ﬁrst three months after allo-SCT. The incidence of grade
II-IV aGVHD was 45% (95% CI, 36-54%; median onset, 32 days
after allo-SCT). In the subgroup of patients for whom all tested
cytokines could be measured closely, but rigorously prior to
aGVHD clinical onset, a high IL-12p70 level (P  104) was
signiﬁcantly associated with the development of clinically signiﬁ-
cant grade II-IV aGVHD. IL-12p70 levels were signiﬁcantly cor-
related to the severity of aGVHD: grade 0-I, median 468 pg/ml;
grade II, median 2538 pg/ml; and grade III-IV, median 4615
pg/mL (P  .0001). In patients experiencing grade II-IV aGVHD,
IL-12p70 levels decreased after aGVHD therapy. Interestingly, we
found a more rapid recovery of monocytes, the main pool of
IL-12p70-secreting myeloid dendritic cells (DC), prior to aGVHD
clinical onset in patients with grade II-IV aGVHD, as compared to
patients with grade 0-I aGVHD (median, 829/L vs. 552/L; P 
.005). At the effector level, we observed a signiﬁcantly more robust
recovery of genuine naive CD3CD4CD45RACD27 T
cells prior to aGVHD clinical onset, in patients with grade II-IV
aGVHD, as compared to patients with grade 0-I aGVHD (median,
50/L vs. 16/L; P  .006). In multivariate analysis, IL-12p70
level measured before aGVHD clinical onset was the strongest
predictive factor for aGVHD development and severity (P 104;
RR  10.7; 95% CI, 3.8-30.6). Overall, these ﬁndings reconstitute
a genuine Th1 loop, supporting a model where aGVHD primarily
reﬂects a type 1 alloreaction (rapid monocytes/DC recovery, IL-
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